Literature DB >> 34718459

Pooling Sputum Samples for Efficient Mass Tuberculosis Screening in Prisons.

Paulo César Pereira Dos Santos1, Andrea da Silva Santos1, Roberto Dias de Oliveira2, Bruna Oliveira da Silva1, Thiego Ramon Soares1, Leonardo Martinez3, Renu Verma4, Jason R Andrews4, Julio Croda5.   

Abstract

BACKGROUND: Although systematic tuberculosis screening in high-risk groups is recommended by the World Health Organization (WHO), implementation in prisons has been limited due to resource constraints. Whether Xpert Ultra sputum pooling could be a sensitive and efficient approach to mass screening in prisons is unknown.
METHODS: In total, 1280 sputum samples were collected from incarcerated individuals in Brazil during mass screening and tested using Xpert G4. We selected samples for mixing in pools of 4, 8, 12, and 16, which were then tested using Ultra. In each pool, a single positive sample of differing Xpert mycobacterial loads was used. Additionally, 10 pools of 16 negative samples each were analyzed as controls. We then simulated tuberculosis screening at prevalences of 0.5-5% and calculated the cost per tuberculosis case detected at different sputum pooling sizes.
RESULTS: The sensitivity and specificity of sputum pooling were high (sensitivity: 94%; 95% confidence interval [CI]: 88-98; specificity: 100%, 95% CI: 84-100). Sensitivity was greater in pools in which the positive sample had a high mycobacterial load compared to those that were very low (100% vs 88%). In settings with a higher tuberculosis prevalence, pools of 4 and 8 were more efficient than larger pool sizes. Larger pools decreased the costs by 87% at low prevalences, whereas smaller pools led to greater cost savings at higher prevalence at higher prevalences (57%).
CONCLUSIONS: Sputum pooling using Ultra was a sensitive strategy for tuberculosis screening. This approach was more efficient than individual testing across a broad range of simulated tuberculosis prevalence settings and could enable active case finding to be scaled while containing costs.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  mass screening; prison; sputum pooling; tuberculosis

Mesh:

Year:  2022        PMID: 34718459      PMCID: PMC9258923          DOI: 10.1093/cid/ciab847

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  36 in total

1.  Evaluation of pooled rapid HIV antibody screening of patients admitted to a San Diego Hospital.

Authors:  Sanjay R Mehta; Vu T Nguyen; Georgina Osorio; Susan Little; Davey M Smith
Journal:  J Virol Methods       Date:  2011-04-12       Impact factor: 2.014

Review 2.  The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection.

Authors:  O Opota; J Mazza-Stalder; G Greub; K Jaton
Journal:  Clin Microbiol Infect       Date:  2019-03-28       Impact factor: 8.067

3.  Tuberculosis in a southern Brazilian prison.

Authors:  Daniele Kuhleis; Andrezza Wolowski Ribeiro; Elis Regina Dalla Costa; Patrícia Izquierdo Cafrune; Karen Barros Schmid; Lucas Laux da Costa; Marta Osório Ribeiro; Arnaldo Zaha; Maria Lucia Rosa Rossetti
Journal:  Mem Inst Oswaldo Cruz       Date:  2012-11       Impact factor: 2.743

Review 4.  A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

Authors:  Jonathon R Campbell; Thenuga Sasitharan; Fawziah Marra
Journal:  Appl Health Econ Health Policy       Date:  2015-08       Impact factor: 2.561

5.  Prevalence of pulmonary tuberculosis and comparative evaluation of screening strategies in a Brazilian prison.

Authors:  A Sanchez; G Gerhardt; S Natal; D Capone; A Espinola; W Costa; J Pires; A Barreto; E Biondi; B Larouzé
Journal:  Int J Tuberc Lung Dis       Date:  2005-06       Impact factor: 2.373

6.  Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting.

Authors:  Wendy Stevens; Lesley Scott; Rebecca H Berhanu; Anura David; Pedro da Silva; Kate Shearer; Ian Sanne
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

Review 7.  The escalating tuberculosis crisis in central and South American prisons.

Authors:  Katharine S Walter; Leonardo Martinez; Denise Arakaki-Sanchez; Victor G Sequera; G Estigarribia Sanabria; Ted Cohen; Albert I Ko; Alberto L García-Basteiro; Zulma Vanessa Rueda; Rafael A López-Olarte; Marcos A Espinal; Julio Croda; Jason R Andrews
Journal:  Lancet       Date:  2021-04-08       Impact factor: 202.731

8.  Half of Pulmonary Tuberculosis Cases Were Left Undiagnosed in Prisons of the Tigray Region of Ethiopia: Implications for Tuberculosis Control.

Authors:  Kelemework Adane; Mark Spigt; Semaw Ferede; Tsehaye Asmelash; Markos Abebe; Geert-Jan Dinant
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

9.  Can the High Sensitivity of Xpert MTB/RIF Ultra Be Harnessed to Save Cartridge Costs? Results from a Pooled Sputum Evaluation in Cambodia.

Authors:  Monyrath Chry; Marina Smelyanskaya; Mom Ky; Andrew J Codlin; Danielle Cazabon; Mao Tan Eang; Jacob Creswell
Journal:  Trop Med Infect Dis       Date:  2020-02-15

10.  Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.

Authors:  Susan E Dorman; Samuel G Schumacher; David Alland; Pamela Nabeta; Derek T Armstrong; Bonnie King; Sandra L Hall; Soumitesh Chakravorty; Daniela M Cirillo; Nestani Tukvadze; Nino Bablishvili; Wendy Stevens; Lesley Scott; Camilla Rodrigues; Mubin I Kazi; Moses Joloba; Lydia Nakiyingi; Mark P Nicol; Yonas Ghebrekristos; Irene Anyango; Wilfred Murithi; Reynaldo Dietze; Renata Lyrio Peres; Alena Skrahina; Vera Auchynka; Kamal Kishore Chopra; Mahmud Hanif; Xin Liu; Xing Yuan; Catharina C Boehme; Jerrold J Ellner; Claudia M Denkinger
Journal:  Lancet Infect Dis       Date:  2017-11-30       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.